125 results on '"Yarnold J"'
Search Results
2. How Low Can You Go? The Radiobiology of Hypofractionation.
- Author
-
Brand DH, Kirby AM, Yarnold JR, and Somaiah N
- Subjects
- Breast pathology, Humans, Male, Radiation Dose Hypofractionation, Radiobiology, Treatment Outcome, Breast Neoplasms radiotherapy, Prostatic Neoplasms radiotherapy
- Abstract
Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) schedules, with some reaching UK standard of care (e.g. adjuvant breast). Hypofractionation exerts varying influences on each of the major clinical end points of radiotherapy studies: acute toxicity, late toxicity and local control. This review will discuss these effects from the viewpoint of the traditional 5 Rs of radiobiology, before considering non-canonical radiobiological effects that may be relevant to ultrahypofractionated radiotherapy. The principles outlined here may assist the reader in their interpretation of the wealth of clinical data presented in the tumour site-specific articles in this special issue., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.
- Author
-
Brunt AM, Haviland JS, Kirby AM, Somaiah N, Wheatley DA, Bliss JM, and Yarnold JR
- Subjects
- Female, Humans, Mastectomy, Mastectomy, Segmental, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Radiotherapy, Adjuvant, Breast Neoplasms pathology
- Abstract
Introduction: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in relation to implementing this schedule., Ipsilateral Breast Tumour Relapse (ibtr): Published estimated 5-year IBTR with 95% CI after 40 Gy in 15 fractions was 2.1% (95% CI 1.4-3.1), 1.7% (1.2-1.6) after 27 Gy and 1.4% (0.2-2.2) after 26 Gy, emphatically showing non-inferiority of the 5-fraction regimens. Subgroup analyses comparing IBTR in 26 Gy versus 40 Gy show no evidence of differential effect regarding age, grade, pathological tumour size, nodal status, tumour bed boost, adjuvant chemotherapy, HER2 status and triple negative status. The number of events in these analyses is small and results should be interpreted with caution. There was only 1 IBTR event post-mastectomy., Normal Tissue Effects: The 26 Gy schedule, on the basis of similar NTE to 40 Gy in 15 fractions, is the recommended regimen for clinical implementation. There is a low absolute rate of moderate/marked NTE, these are predominantly moderate not severe change. Subgroup analyses comparing clinician-assessed moderate or marked adverse effect for 26 Gy versus 40 Gy show no evidence of differential effects according to age, breast size, surgical deficit, tumour bed boost, or adjuvant chemotherapy., Radiobiological Considerations: The design of the FAST-Forward trial does not control for time-related effects, and the ability to interpret clinical outcomes in terms of underlying biology is limited. There could conceivably be a time-effect for tumour control. A slight reduction in α/β estimate for the late normal tissue effects of test regimens might be a chance effect, but if real could reflect fewer consequential late effects due to lower rates of moist desquamation., Conclusion: The 26 Gy 5-fraction daily regimen for breast radiotherapy can be implemented now., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
4. Intratumoral Hydrogen Peroxide With Radiation Therapy in Locally Advanced Breast Cancer: Results From a Phase 1 Clinical Trial.
- Author
-
Nimalasena S, Gothard L, Anbalagan S, Allen S, Sinnett V, Mohammed K, Kothari G, Musallam A, Lucy C, Yu S, Nayamundanda G, Kirby A, Ross G, Sawyer E, Castell F, Cleator S, Locke I, Tait D, Westbury C, Wolstenholme V, Box C, Robinson SP, Yarnold J, and Somaiah N
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor blood, Breast Neoplasms blood, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Breast Neoplasms, Male blood, Breast Neoplasms, Male pathology, Breast Neoplasms, Male therapy, Chemokine CCL3 blood, Dose Fractionation, Radiation, Female, Humans, Hyaluronic Acid administration & dosage, Hydrogen Peroxide adverse effects, Injections, Intralesional adverse effects, Injections, Intralesional methods, Interleukin-1beta blood, Interleukin-4 blood, Lymphatic Irradiation, Male, Middle Aged, Oxidants adverse effects, Pain Measurement, Pain, Procedural chemically induced, Radiodermatitis pathology, Skin drug effects, TNF-Related Apoptosis-Inducing Ligand blood, Ultrasonography, Interventional, Viscosupplements administration & dosage, Breast Neoplasms therapy, Chemoradiotherapy methods, Hydrogen Peroxide administration & dosage, Oxidants administration & dosage
- Abstract
Purpose: Hydrogen peroxide (H
2 O2 ) plays a vital role in normal cellular processes but at supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is potentially exploitable for the treatment of cancer in combination with radiation therapy (RT). We report the first phase 1 trial testing the safety and tolerability of intratumoral H2 O2 + external beam RT as a novel combination in patients with breast cancer and exploratory plasma marker analyses investigating possible mechanisms of action., Methods and Materials: Twelve patients with breast tumors ≥3 cm (surgically or medically inoperable) received intratumoral H2 O2 with either 36 Gy in 6 twice-weekly fractions (n = 6) or 49.5 Gy in 18 daily fractions (n = 6) to the whole breast ± locoregional lymph nodes in a single-center, nonrandomized study. H2 O2 was mixed in 1% sodium hyaluronate gel (final H2 O2 concentration 0.5%) before administration to slow drug release and minimize local discomfort. The mixture was injected intratumorally under ultrasound guidance twice weekly 1 hour before RT. The primary endpoint was patient-reported maximum intratumoral pain intensity before and 24 hours postinjection. Secondary endpoints included grade ≥3 skin toxicity and tumor response by ultrasound. Blood samples were collected before, during, and at the end of treatment for cell-death and immune marker analysis., Results: Compliance with H2 O2 and RT was 100%. Five of 12 patients reported moderate pain after injection (grade 2 Common Terminology Criteria for Adverse Events v4.02) with median duration 60 minutes (interquartile range, 20-120 minutes). Skin toxicity was comparable to RT alone, with maintained partial/complete tumor response relative to baseline in 11 of 12 patients at last follow-up (median 12 months). Blood marker analysis highlighted significant associations of TRAIL, IL-1β, IL-4, and MIP-1α with tumor response., Conclusions: Intratumoral H2 O2 with RT is well tolerated with no additional toxicity compared with RT alone. If efficacy is confirmed in a randomized phase 2 trial, the approach has potential as a cost-effective radiation response enhancer in multiple cancer types in which locoregional control after RT alone remains poor., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
5. Changes in radiotherapy fractionation-breast cancer.
- Author
-
Yarnold J
- Subjects
- Breast Neoplasms surgery, Female, Humans, Lymphatic Metastasis radiotherapy, Mastectomy, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant adverse effects, Breast Neoplasms radiotherapy, Radiation Dose Hypofractionation
- Abstract
Conventional fractionation for half a century has been justified on the basis that 2.0 Gy fractions spare dose-limiting late-responding normal tissues to a greater degree than cancerous tissues. Early indications that breast cancer responds more strongly to fraction size than many other common cancers were followed several decades of investigation, but there is now reliable Level I evidence that this is the case. Four randomised trials testing fraction sizes in the range 2.7-3.3 Gy have reported 10-year follow up in almost 8000 patients, and they provide robust estimates of α/β in the range of 3 Gy. The implication is that there are no advantages in terms of safety or effectiveness of persisting with 2.0 Gy fractions in patients with breast cancer. 15- or 16-fraction schedules are replacing the conventional 25-fraction regimen as a standard of care for adjuvant therapy in an increasing number of countries. A number of concerns relating to the appropriateness of hypofractionation in patient subgroups, including those treated post-mastectomy, advanced local-regional disease and/or to lymphatic pathways are addressed. Meanwhile, hypofractionation can be exploited to modulate dose intensity across the breast according to relapse risk by varying fraction size across the treatment volume. The lower limits of hypofractionation are currently being explored, one approach testing a 5-fraction schedule of local-regional radiotherapy delivered in 1 week.
- Published
- 2019
- Full Text
- View/download PDF
6. FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
- Author
-
Wilkins A, Chauhan R, Rust A, Pearson A, Daley F, Manodoro F, Fenwick K, Bliss J, Yarnold J, and Somaiah N
- Subjects
- Breast Neoplasms therapy, Combined Modality Therapy, DNA Copy Number Variations, Exome, Female, Gene Expression Profiling, Genetic Testing, High-Throughput Nucleotide Sequencing, Humans, Reproducibility of Results, Treatment Outcome, Breast Neoplasms genetics, Breast Neoplasms pathology, DNA, Neoplasm, Genetic Predisposition to Disease, Germ Cells metabolism
- Abstract
Background: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood., Methods: Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents (Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 (Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy number abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate somatic variants and CNA, respectively., Results: Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% were more difficult to validate irrespective of the type of germline DNA used. Pearson's correlation coefficients for paired comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94., Conclusions: There is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material.
- Published
- 2018
- Full Text
- View/download PDF
7. The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.
- Author
-
Bartlett FR, Donovan EM, McNair HA, Corsini LA, Colgan RM, Evans PM, Maynard L, Griffin C, Haviland JS, Yarnold JR, and Kirby AM
- Subjects
- Aged, Coronary Vessels radiation effects, Female, Heart radiation effects, Humans, Lung radiation effects, Middle Aged, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Tomography, X-Ray Computed, Breast Neoplasms radiotherapy, Breath Holding, Organs at Risk radiation effects
- Abstract
Aims: To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting., Materials and Methods: Patients were recruited from 10 UK centres. Following surgery for early left breast cancer, patients with any heart inside the 50% isodose from a standard free-breathing tangential field treatment plan underwent a second planning computed tomography (CT) scan using the VBH technique. A separate treatment plan was prepared on the VBH CT scan and used for treatment. The mean heart, left anterior descending coronary artery (LAD) and lung doses were calculated. Daily electronic portal imaging (EPI) was carried out and scanning/treatment times were recorded. The primary end point was the percentage of patients achieving a reduction in mean heart dose with VBH. Population systematic (Σ) and random errors (σ) were estimated. Within-patient comparisons between techniques used Wilcoxon signed-rank tests., Results: In total, 101 patients were recruited during 2014. Primary end point data were available for 93 patients, 88 (95%) of whom achieved a reduction in mean heart dose with VBH. Mean cardiac doses (Gy) for free-breathing and VBH techniques, respectively, were: heart 1.8 and 1.1, LAD 12.1 and 5.4, maximum LAD 35.4 and 24.1 (all P<0.001). Population EPI-based displacement data showed Σ =+1.3-1.9 mm and σ=1.4-1.8 mm. Median CT and treatment session times were 21 and 22 min, respectively., Conclusions: The VBH technique is confirmed as effective in sparing heart tissue and is feasible in a multicentre setting., (Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
8. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
- Author
-
Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, and Bliss JM
- Subjects
- Female, Humans, Radiation Injuries, Radiodermatitis, Radiotherapy Dosage, Breast radiation effects, Breast Neoplasms radiotherapy, Skin radiation effects
- Abstract
Background and Purpose: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions., Material and Methods: Patients were randomly allocated to 40Gy/15 fractions (F)/3-weeks, 27Gy/5F/1-week or 26Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4weeks after completion., Results: 190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40Gy/15F 6/44 (13.6%); 27Gy/5F 5/51 (9.8%); 26Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40Gy/15F 0/43; 27Gy/5F 1/41 (2.4%); 26Gy/5F 0/53., Conclusions: Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild., (Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
- Author
-
Haviland JS, Hopwood P, Mills J, Sydenham M, Bliss JM, and Yarnold JR
- Subjects
- Adult, Aged, Aged, 80 and over, Early Diagnosis, Female, Humans, Middle Aged, Patient Reported Outcome Measures, Prognosis, Proportional Hazards Models, Breast radiation effects, Breast Neoplasms radiotherapy, Dose Fractionation, Radiation
- Abstract
Aims: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data from the Standardisation of Breast Radiotherapy (START) trials are examined., Materials and Methods: NTEs in the treated breast were recorded by (i) annual clinical assessments, (ii) photographs at 2 and 5 years, (iii) PROMs at 6 months, 1, 2 and 5 years after radiotherapy. Hazard ratios for the radiotherapy schedules were compared. Measures of agreement of assessments at 2 and 5 years tested concordance., Results: PROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had clinical and 1444 had photographic assessments. All methods were sensitive to the dose difference between schedules. Patients reported a higher prevalence for all NTE end points than clinicians or photographs (P < 0.001 for most NTEs). Concordance was generally poor; weighted kappa at 2 years ranged from 0.05 (telangiectasia) to 0.21 (shrinkage and oedema). The percentage agreement was lowest between PROMs and photographic assessments of change in breast appearance (38%)., Conclusions: All three methods produced similar conclusions for the comparison of trial schedules, despite low concordance between the methods on an individual patient basis. Careful consideration should be given to the different contributions of the measures of NTE in future radiotherapy trials., (Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy.
- Author
-
Somaiah N, Chua ML, Bourne S, Daley F, A' Hern R, Nuta O, Gothard L, Boyle S, Herskind C, Pearson A, Warrington J, Helyer S, Owen R, Rothkamm K, and Yarnold J
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Lymphocytes radiation effects, Middle Aged, Radiotherapy Dosage, Skin metabolism, Breast radiation effects, Breast Neoplasms radiotherapy, DNA Breaks, Double-Stranded, Skin radiation effects
- Abstract
Aim: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT)., Patients and Methods: Patients given whole breast RT ⩾5years earlier were identified on the basis of moderate/marked or minimal/no adverse effects despite the absence ('RT-Sensitive', RT-S) or presence ('RT-Resistant', RT-R) of variables predisposing to late adverse effects. Residual DSB were quantified in skin 24h after a 4Gy test dose in 20 RT-S and 15 RT-R patients. Residual DSB were quantified in lymphocytes irradiated with 4Gy in vitro in 30/35 patients., Results: Mean foci per dermal fibroblast were 3.29 (RT-S) vs 2.80 (RT-R) (p=0.137); 3.28 (RT-S) vs 2.60 (RT-R) in endothelium (p=0.158); 2.50 (RT-S) vs 2.41 (RT-R) in suprabasal keratinocytes (p=0.633); 2.70 (RT-S) vs 2.35 (RT-R) in basal epidermis (p=0.419); 12.1 (RT-S) vs 10.3 (RT-R) in lymphocytes (p=0.0052)., Conclusions: Residual DSB in skin following a 4Gy dose were not significantly associated with risk of late adverse effects of breast radiotherapy, although exploratory analyses suggested an association in severely affected individuals. By contrast, a significant association was detected based on the in vitro response of lymphocytes., (Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
11. Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
- Author
-
Nuta O, Somaiah N, Boyle S, Chua ML, Gothard L, Yarnold J, Rothkamm K, and Herskind C
- Subjects
- Aged, Aged, 80 and over, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cells, Cultured, DNA Breaks, Double-Stranded, Female, Fibroblasts metabolism, Fibroblasts pathology, Humans, Microscopy, Fluorescence, Middle Aged, Radiation Injuries etiology, Radiation Injuries metabolism, Radiation Injuries pathology, Radiation Tolerance, Randomized Controlled Trials as Topic, Tumor Suppressor Protein p53 metabolism, Breast Neoplasms radiotherapy, Fibroblasts radiation effects
- Abstract
Late normal tissue toxicity varies widely between patients and limits breast radiotherapy dose. Here we aimed to determine its relationship to DNA damage responses of fibroblast cultures from individual patients. Thirty-five breast cancer patients, with minimal or marked breast changes after breast-conserving therapy consented to receive a 4 Gy test irradiation to a small skin field of the left buttock and have punch biopsies taken from irradiated and unirradiated skin. Early-passage fibroblast cultures were established by outgrowth and irradiated in vitro with 0 or 4 Gy. 53BP1 foci, p53 and p21/CDKN1A were detected by immunofluorescence microscopy. Residual 53BP1 foci counts 24 h after in vitro irradiation were significantly higher in fibroblasts from RT-sensitive versus RT-resistant patients. Furthermore, significantly larger fractions of p53- but not p21/CDKN1A-positive fibroblasts were found in cultures from RT-sensitive patients without in vitro irradiation, and 2 h and 6 d post-irradiation. Exploratory analysis showed a stronger p53 response 2 h after irradiation of fibroblasts established from patients with severe reaction. These results associate the radiation response of fibroblasts with late reaction of the breast after RT and suggest a correlation with severity., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
12. Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
- Author
-
Dorling L, Barnett GC, Michailidou K, Coles CE, Burnet NG, Yarnold J, Elliott RM, Dunning AM, Pharoah PD, and West CM
- Subjects
- Alleles, Breast Neoplasms pathology, Cohort Studies, Combined Modality Therapy, Female, Genotype, Humans, Odds Ratio, Polymorphism, Single Nucleotide, Risk, Tumor Burden, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Genetic Predisposition to Disease, Radiation Tolerance genetics
- Abstract
Purpose: It has been hypothesized that increased predisposition to breast cancer may correlate with radiosensitivity, and thus increased risk of toxicity following breast irradiation. This study investigated the relationship between common breast cancer risk variants and radiotherapy toxicity., Experimental Design: SNP genotypes were determined in female breast cancer patients from the RAPPER (Radiogenomics: Assessment of polymorphisms for predicting the effects of radiotherapy) study using the Illumina CytoSNP12 genome-wide array. A further 15,582,449 genotypes were imputed using the 1000 Genomes Project reference panel. Patient (n = 1,160) polygenic risk scores were generated by summing risk-allele dosages, both unweighted and weighted by published effect sizes for breast cancer risk. Regression models were used to test associations of individual variants and polygenic risk scores with acute and late toxicity phenotypes (telangiectasia, breast edema, photographically assessed shrinkage, induration, pigmentation, breast pain, breast sensitivity, and overall toxicity)., Results: Genotypes of 90 confirmed breast cancer risk variants were accurately determined and polygenic risk scores were approximately normally distributed. Variant rs6964587 was associated with increased breast edema 5 years following radiotherapy (Beta, 0.22; 95% confidence interval, 0.09-0.34; P = 7 × 10(-4)). No other associations were found between individual variants or the unweighted (P > 0.17) or weighted (P > 0.13) polygenic risk score and radiotherapy toxicity. This study had >87% power to detect an association between the polygenic risk score (relative risk > 1.1) and toxicity., Conclusions: Cancer patients with a high polygenic predisposition to breast cancer do not have an increased risk of radiotherapy toxicity up to 5 years following radiotherapy but individual variants may increase risk., (©2015 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
13. Accelerated partial breast irradiation: the new standard?
- Author
-
Coles CE and Yarnold JR
- Subjects
- Female, Humans, Brachytherapy methods, Breast Neoplasms radiotherapy, Carcinoma in Situ radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2016
- Full Text
- View/download PDF
14. A multicentre study of the evidence for customized margins in photon breast boost radiotherapy.
- Author
-
Harris EJ, Mukesh MB, Donovan EM, Kirby AM, Haviland JS, Jena R, Yarnold J, Baker A, Dean J, Eagle S, Mayles H, Griffin C, Perry R, Poynter A, Coles CE, and Evans PM
- Subjects
- Adult, Aged, Aged, 80 and over, Anatomic Landmarks, Breast Neoplasms pathology, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Patient Positioning, Photons, Radiographic Image Interpretation, Computer-Assisted, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Image-Guided, United Kingdom, Breast Neoplasms diagnostic imaging, Breast Neoplasms radiotherapy, Cone-Beam Computed Tomography methods, Radiotherapy Setup Errors prevention & control
- Abstract
Objective: To determine if subsets of patients may benefit from smaller or larger margins when using laser setup and bony anatomy verification of breast tumour bed (TB) boost radiotherapy (RT)., Methods: Verification imaging data acquired using cone-beam CT, megavoltage CT or two-dimensional kilovoltage imaging on 218 patients were used (1574 images). TB setup errors for laser-only setup (dlaser) and for bony anatomy verification (dbone) were determined using clips implanted into the TB as a gold standard for the TB position. Cases were grouped by centre-, patient- and treatment-related factors, including breast volume, TB position, seroma visibility and surgical technique. Systematic (Σ) and random (σ) TB setup errors were compared between groups, and TB planning target volume margins (MTB) were calculated., Results: For the study population, Σlaser was between 2.8 and 3.4 mm, and Σbone was between 2.2 and 2.6 mm, respectively. Females with larger breasts (p = 0.03), easily visible seroma (p ≤ 0.02) and open surgical technique (p ≤ 0.04) had larger Σlaser. Σbone was larger for females with larger breasts (p = 0.02) and lateral tumours (p = 0.04). Females with medial tumours (p < 0.01) had smaller Σbone., Conclusion: If clips are not used, margins should be 8 and 10 mm for bony anatomy verification and laser setup, respectively. Individualization of TB margins may be considered based on breast volume, TB and seroma visibility., Advances in Knowledge: Setup accuracy using lasers and bony anatomy is influenced by patient and treatment factors. Some patients may benefit from clip-based image guidance more than others.
- Published
- 2016
- Full Text
- View/download PDF
15. Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues.
- Author
-
Yarnold J, Somaiah N, and Bliss JM
- Subjects
- Adult, Aged, Breast Neoplasms genetics, Breast Neoplasms pathology, Breast Neoplasms surgery, Canada, DNA Damage radiation effects, DNA End-Joining Repair, Female, Humans, Intraoperative Care, Middle Aged, Organ Size, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated, Randomized Controlled Trials as Topic, United Kingdom, Breast anatomy & histology, Breast Neoplasms radiotherapy, Radiation Dose Hypofractionation
- Published
- 2015
- Full Text
- View/download PDF
16. In Regard to Vaidya et al.
- Author
-
Yarnold J and Bentzen SM
- Subjects
- Female, Humans, Breast Neoplasms radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2015
- Full Text
- View/download PDF
17. XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.
- Author
-
Seibold P, Behrens S, Schmezer P, Helmbold I, Barnett G, Coles C, Yarnold J, Talbot CJ, Imai T, Azria D, Koch CA, Dunning AM, Burnet N, Bliss JM, Symonds RP, Rattay T, Suga T, Kerns SL, Bourgier C, Vallis KA, Sautter-Bihl ML, Claßen J, Debus J, Schnabel T, Rosenstein BS, Wenz F, West CM, Popanda O, and Chang-Claude J
- Subjects
- Adult, Aged, Aged, 80 and over, Alleles, Breast pathology, Cohort Studies, Female, Fibrosis genetics, Genome-Wide Association Study, Germany, Humans, Middle Aged, Odds Ratio, Oxidative Stress genetics, Phenotype, Predictive Value of Tests, Radiation Injuries pathology, Radiation Tolerance genetics, X-ray Repair Cross Complementing Protein 1, Breast radiation effects, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, DNA-Binding Proteins genetics, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Radiation Injuries genetics
- Abstract
Purpose: To identify single-nucleotide polymorphisms (SNPs) in oxidative stress-related genes associated with risk of late toxicities in breast cancer patients receiving radiation therapy., Methods and Materials: Using a 2-stage design, 305 SNPs in 59 candidate genes were investigated in the discovery phase in 753 breast cancer patients from 2 prospective cohorts from Germany. The 10 most promising SNPs in 4 genes were evaluated in the replication phase in up to 1883 breast cancer patients from 6 cohorts identified through the Radiogenomics Consortium. Outcomes of interest were late skin toxicity and fibrosis of the breast, as well as an overall toxicity score (Standardized Total Average Toxicity). Multivariable logistic and linear regression models were used to assess associations between SNPs and late toxicity. A meta-analysis approach was used to summarize evidence., Results: The association of a genetic variant in the base excision repair gene XRCC1, rs2682585, with normal tissue late radiation toxicity was replicated in all tested studies. In the combined analysis of discovery and replication cohorts, carrying the rare allele was associated with a significantly lower risk of skin toxicities (multivariate odds ratio 0.77, 95% confidence interval 0.61-0.96, P=.02) and a decrease in Standardized Total Average Toxicity scores (-0.08, 95% confidence interval -0.15 to -0.02, P=.016)., Conclusions: Using a stage design with replication, we identified a variant allele in the base excision repair gene XRCC1 that could be used in combination with additional variants for developing a test to predict late toxicities after radiation therapy in breast cancer patients., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
18. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
- Author
-
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, and Dabakuyo-Yonli TS
- Subjects
- Breast Neoplasms diagnosis, Breast Neoplasms mortality, Consensus, Delphi Technique, Disease Progression, Disease-Free Survival, Endpoint Determination classification, Female, Humans, Randomized Controlled Trials as Topic classification, Time Factors, Treatment Failure, Breast Neoplasms therapy, Endpoint Determination standards, Randomized Controlled Trials as Topic standards, Research Design standards, Terminology as Topic
- Abstract
Background: Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for randomized cancer clinical trials (RCTs) in breast cancer., Patients and Methods: A literature review was carried out to identify TTE end points (primary or secondary) reported in publications of randomized trials or guidelines. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points based on a validated consensus method that formalize the degree of agreement among experts., Results: Recommended guidelines for the definitions of TTE end points commonly used in RCTs for breast cancer are provided for non-metastatic and metastatic settings., Conclusion: The use of standardized definitions should facilitate comparisons of trial results and improve the quality of trial design and reporting. These guidelines could be of particular interest to those involved in the design, conducting, reporting, or assessment of RCT., (© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
19. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.
- Author
-
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, and Poortmans P
- Subjects
- Axilla, Breast Neoplasms pathology, Consensus, Female, Humans, Lymph Nodes pathology, Lymphatic Metastasis, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local prevention & control, Observer Variation, Radiography, Interventional methods, Radiotherapy, Image-Guided methods, Tomography, X-Ray Computed standards, Breast Neoplasms radiotherapy
- Abstract
Background and Purpose: Delineation of clinical target volumes (CTVs) is a weak link in radiation therapy (RT), and large inter-observer variation is seen in breast cancer patients. Several guidelines have been proposed, but most result in larger CTVs than based on conventional simulator-based RT. The aim was to develop a delineation guideline obtained by consensus between a broad European group of radiation oncologists., Material and Methods: During ESTRO teaching courses on breast cancer, teachers sought consensus on delineation of CTV through dialogue based on cases. One teacher delineated CTV on CT scans of 2 patients, followed by discussion and adaptation of the delineation. The consensus established between teachers was sent to other teams working in the same field, both locally and on a national level, for their input. This was followed by developing a broad consensus based on discussions., Results: Borders of the CTV encompassing a 5mm margin around the large veins, running through the regional lymph node levels were agreed, and for the breast/thoracic wall other vessels were pointed out to guide delineation, with comments on margins for patients with advanced breast cancer., Conclusion: The ESTRO consensus on CTV for elective RT of breast cancer, endorsed by a broad base of the radiation oncology community, is presented to improve consistency., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time?
- Author
-
Kaidar-Person O, Poortmans P, Klimberg S, Haviland J, Offersen B, Audisio R, and Yarnold J
- Subjects
- Animals, Female, Humans, Breast Neoplasms therapy, Decision Support Techniques, Randomized Controlled Trials as Topic methods
- Published
- 2014
- Full Text
- View/download PDF
21. Is current evidence about intraoperative partial breast irradiation sufficient for broad implementation in clinical practice?
- Author
-
Kaidar-Person O, Yarnold J, Offersen BV, and Poortmans P
- Subjects
- Brachytherapy methods, Breast Neoplasms mortality, Breast Neoplasms pathology, Evidence-Based Medicine, Female, Humans, Incidence, Mastectomy methods, Mastectomy, Segmental methods, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Prognosis, Radiotherapy Dosage, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated methods, Randomized Controlled Trials as Topic, Risk Assessment, Survival Analysis, Treatment Outcome, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Intraoperative Care methods, Neoplasm Recurrence, Local epidemiology
- Published
- 2014
- Full Text
- View/download PDF
22. Radiotherapy for breast cancer, the TARGIT-A trial.
- Author
-
Yarnold J, Offersen BV, Olivotto I, Poortmans P, and Sarin R
- Subjects
- Female, Humans, Breast Neoplasms radiotherapy, Carcinoma, Ductal, Breast radiotherapy
- Published
- 2014
- Full Text
- View/download PDF
23. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
- Author
-
Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, and West CM
- Subjects
- Dose-Response Relationship, Radiation, Female, Gene Frequency, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Male, Polymorphism, Single Nucleotide, Prospective Studies, Radiotherapy, Adjuvant adverse effects, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Genetic Variation, Prostatic Neoplasms genetics, Prostatic Neoplasms radiotherapy, Radiation Injuries genetics, Radiotherapy, Intensity-Modulated adverse effects
- Abstract
Background and Purpose: This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity 2years after radiotherapy., Materials and Methods: A genome wide association study was performed in 1850 patients from the RAPPER study: 1217 received adjuvant breast radiotherapy and 633 had radical prostate radiotherapy. Genotype associations with both overall and individual endpoints of toxicity were tested via univariable and multivariable regression. Replication of potentially associated SNPs was carried out in three independent patient cohorts who had radiotherapy for prostate (516 RADIOGEN and 862 Gene-PARE) or breast (355 LeND) cancer., Results: Quantile-quantile plots show more associations at the P<5×10(-7) level than expected by chance (164 vs. 9 for the prostate cases and 29 vs. 4 for breast cases), providing evidence that common genetic variants are associated with risk of toxicity. Strongest associations were for individual endpoints rather than an overall measure of toxicity in all patients. However, in general, significant associations were not validated at a nominal 0.05 level in the replication cohorts., Conclusions: This largest GWAS to date provides evidence of true association between common genetic variants and toxicity. Associations with toxicity appeared to be tumour site-specific. Future GWAS require higher statistical power, in particular in the validation stage, to test clinically relevant effect sizes of SNP associations with individual endpoints, but the required sample sizes are achievable., (Copyright © 2014. Published by Elsevier Ireland Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
24. DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.
- Author
-
Chua ML, Horn S, Somaiah N, Davies S, Gothard L, A'Hern R, Yarnold J, and Rothkamm K
- Subjects
- Adult, Aged, Apoptosis drug effects, Ataxia Telangiectasia Mutated Proteins antagonists & inhibitors, Ataxia Telangiectasia Mutated Proteins metabolism, Case-Control Studies, Chromones pharmacology, DNA Breaks, Double-Stranded drug effects, DNA Repair drug effects, DNA-Activated Protein Kinase antagonists & inhibitors, DNA-Activated Protein Kinase metabolism, Enzyme Activation drug effects, Enzyme Activation radiation effects, Female, Histones metabolism, Humans, Intracellular Signaling Peptides and Proteins metabolism, Lymphocytes cytology, Lymphocytes drug effects, Lymphocytes metabolism, Middle Aged, Morpholines pharmacology, Nuclear Proteins antagonists & inhibitors, Nuclear Proteins metabolism, Organs at Risk radiation effects, Protein Kinase Inhibitors pharmacology, Pyrones pharmacology, Radiation Injuries metabolism, Radiation Tolerance drug effects, Radiation Tolerance radiation effects, Time Factors, Tumor Suppressor p53-Binding Protein 1, Apoptosis radiation effects, Breast Neoplasms radiotherapy, DNA Breaks, Double-Stranded radiation effects, DNA Repair radiation effects, Lymphocytes radiation effects, Radiation Injuries genetics, Radiation Injuries pathology
- Abstract
This study aimed to test whether induction of apoptosis following ex vivo X-irradiation of unstimulated blood lymphocytes correlated with clinical radiosensitivity and DNA double-strand break (DSB) repair in breast radiotherapy patients and healthy volunteers. Using small molecule inhibitors, the relationship between DSB repair and radiation-induced apoptosis was examined. Sixteen breast cancer patients with minimal (controls, n = 8) or extremely marked late radiation-induced change (cases, n = 8) and eight healthy volunteers were selected. DSBs were quantified by γH2AX/53BP1 immunofluorescence, and apoptosis was measured using a fluorogenic inhibitor of caspases assay. Mean γH2AX/53BP1 focus levels 24 h after exposure to 4 Gy were higher in cases (12.7 foci per cell) than in controls (10.3 foci per cell, p = 0.002). In contrast, the mean apoptotic fraction 48 h after 8 Gy was comparable, 37.2 % in cases and 34.7 % in controls (p = 0.442). Residual focus and apoptosis levels were not correlated within individuals (Spearman's R = -0.0059, p = 0.785). However, cells treated with DNA-PK inhibitor Nu7441 had higher focus and apoptosis levels 48 h after 1 Gy compared to mock-treated cells, suggesting that apoptosis induction following irradiation is modulated by DSB repair. This effect required functional ATM since cells treated simultaneously with Nu7441 and the ATM inhibitor Ku55933 were resistant to apoptosis despite high levels of residual foci. One clinical case displayed an impaired DNA-PK-dependent end-joining cellular phenotype. In summary, clinical radiosensitivity may be associated with impaired DSB repair in some patients. Although pharmaceutical inhibition of ATM and DNA-PK affected apoptosis induction and DSB repair, no association was observed between apoptosis and residual focus levels in patients and volunteers.
- Published
- 2014
- Full Text
- View/download PDF
25. Response to D. Woolf and M. Keshtgar's reply to: breast radiotherapy and heart disease - where are we now?
- Author
-
Bartlett FR, Yarnold JR, and Kirby AM
- Subjects
- Female, Humans, Breast Neoplasms radiotherapy, Heart Diseases etiology, Radiation Injuries etiology
- Published
- 2014
- Full Text
- View/download PDF
26. Multileaf collimation cardiac shielding in breast radiotherapy: Cardiac doses are reduced, but at what cost?
- Author
-
Bartlett FR, Yarnold JR, Donovan EM, Evans PM, Locke I, and Kirby AM
- Subjects
- Breast Neoplasms surgery, Female, Humans, Mastectomy, Segmental, Radiation Protection instrumentation, Radiography, Interventional, Radiotherapy, Adjuvant, Tomography, X-Ray Computed, Breast Neoplasms radiotherapy, Heart radiation effects, Radiation Injuries prevention & control, Radiation Protection methods, Radiotherapy Planning, Computer-Assisted methods
- Abstract
Aims: To measure cardiac tissue doses in left-sided breast cancer patients receiving supine tangential field radiotherapy with multileaf collimation (MLC) cardiac shielding of the heart and to assess the effect on target volume coverage., Materials and Methods: Sixty-seven consecutive patients who underwent adjuvant radiotherapy to the left breast (n = 48) or chest wall (n = 19) in 2009/2010 were analysed. The heart, left anterior descending coronary artery (LAD), whole breast and partial breast clinical target volumes (WBCTV and PBCTV) were outlined retrospectively (the latter only in patients who had undergone breast-conserving surgery [BCS]). The mean heart and LAD NTDmean and maximum LAD doses (LADmax) were calculated for all patients (NTDmean is a biologically weighted mean dose normalised to 2 Gy fractions using a standard linear quadratic model). Coverage of WBCTV and PBCTV by the 95% isodose was assessed (BCS patients only)., Results: The mean heart NTDmean (standard deviation) was 0.8 (0.3) Gy, the mean LAD NTDmean 6.7 (4.3) Gy and the mean LADmax 40.3 (10.1) Gy. Coverage of the WBCTV by 95% isodose was <90% in one in three patients and PBCTV coverage <95% (range 78-94%) in one in 10 BCS patients., Conclusion: The use of MLC cardiac shielding reduces doses to cardiac tissues at the expense of target tissue coverage. Formal target volume delineation in combination with an assessment of the likelihood of local relapse is recommended in order to aid decisions regarding field and MLC placement., (Copyright © 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
27. Breast radiotherapy and heart disease - where are we now?
- Author
-
Bartlett FR, Yarnold JR, and Kirby AM
- Subjects
- Breast Neoplasms surgery, Coronary Vessels radiation effects, Female, Humans, Mastectomy, Segmental, Survival Analysis, Breast Neoplasms radiotherapy, Heart Diseases etiology, Radiation Injuries etiology
- Published
- 2013
- Full Text
- View/download PDF
28. Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials.
- Author
-
Mukesh MB, Harris E, Collette S, Coles CE, Bartelink H, Wilkinson J, Evans PM, Graham P, Haviland J, Poortmans P, Yarnold J, and Jena R
- Subjects
- Adult, Aged, Biopsy, Needle, Breast Neoplasms pathology, Breast Neoplasms surgery, Dose-Response Relationship, Radiation, Evaluation Studies as Topic, Female, Fibrosis etiology, Fibrosis pathology, Humans, Immunohistochemistry, Mastectomy, Segmental methods, Middle Aged, Pilot Projects, Probability, Radiotherapy Dosage, Radiotherapy, Adjuvant, Radiotherapy, Conformal methods, Radiotherapy, High-Energy methods, Randomized Controlled Trials as Topic, Reference Values, Risk Assessment, Breast pathology, Breast radiation effects, Breast Neoplasms radiotherapy, Radiotherapy, Conformal adverse effects, Radiotherapy, High-Energy adverse effects
- Abstract
Introduction: The dose-volume effect of radiation therapy on breast tissue is poorly understood. We estimate NTCP parameters for breast fibrosis after external beam radiotherapy., Materials and Methods: We pooled individual patient data of 5856 patients from 2 trials including whole breast irradiation followed with or without a boost. A two-compartment dose volume histogram model was used with boost volume as the first compartment and the remaining breast volume as second compartment. Results from START-pilot trial (n=1410) were used to test the predicted models., Results: 26.8% patients in the Cambridge trial (5 years) and 20.7% patients in the EORTC trial (10 years) developed moderate-severe breast fibrosis. The best fit NTCP parameters were BEUD3(50)=136.4 Gy, γ50=0.9 and n=0.011 for the Niemierko model and BEUD3(50)=132 Gy, m=0.35 and n=0.012 for the Lyman Kutcher Burman model. The observed rates of fibrosis in the START-pilot trial agreed well with the predicted rates., Conclusions: This large multi-centre pooled study suggests that the effect of volume parameter is small and the maximum RT dose is the most important parameter to influence breast fibrosis. A small value of volume parameter 'n' does not fit with the hypothesis that breast tissue is a parallel organ. However, this may reflect limitations in our current scoring system of fibrosis., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
29. Intensity-modulated Radiotherapy for the Treatment of Breast Cancer.
- Author
-
Coles CE, Donovan E, Haviland J, and Yarnold J
- Subjects
- Breast Neoplasms therapy, Female, Humans, Radiotherapy, Intensity-Modulated, Breast Neoplasms radiotherapy
- Published
- 2013
- Full Text
- View/download PDF
30. Breast radiotherapy: less is more?
- Author
-
Coles CE, Brunt AM, Wheatley D, Mukesh MB, and Yarnold JR
- Subjects
- Breast Neoplasms surgery, Clinical Trials as Topic, Dose Fractionation, Radiation, Dose-Response Relationship, Radiation, Female, Humans, Radiotherapy, Adjuvant methods, Breast Neoplasms radiotherapy
- Abstract
A 3 week schedule of whole breast radiotherapy is firmly established in the UK and is becoming more accepted internationally, especially as accelerated partial breast radiotherapy regimens become more common. It seems that a 3 week schedule is unlikely to be the lower limit of whole breast hypofractionation and the partial breast may even be adequately treated with just a single treatment. It is, however, essential that these hypotheses are rigorously tested within well-designed trials to ensure the highest quality of radiotherapy. This overview will address the rationale for hypofractionation in breast cancer, discuss past trials and outline the design of current studies., (Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
31. Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer.
- Author
-
Finnon P, Kabacik S, MacKay A, Raffy C, A'Hern R, Owen R, Badie C, Yarnold J, and Bouffler S
- Subjects
- Adult, Aged, Apoptosis genetics, Breast Neoplasms surgery, Case-Control Studies, Cluster Analysis, DNA Breaks, Double-Stranded radiation effects, Female, Humans, Micronucleus Tests, Middle Aged, Randomized Controlled Trials as Topic, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Gene Expression Regulation, Neoplastic, Lymphocytes radiation effects, Radiation Tolerance genetics, Radiotherapy, Adjuvant adverse effects
- Abstract
Background and Purpose: Identification of mechanisms of late normal tissue responses to curative radiotherapy that discriminate individuals with marked or mild responses would aid response prediction. This study aimed to identify differences in gene expression, apoptosis, residual DNA double strand breaks and chromosomal damage after in vitro irradiation of lymphocytes in a series of patients with marked (31 cases) or mild (28 controls) late adverse reaction to adjuvant breast radiotherapy., Materials and Methods: Gene expression arrays, residual γH2AX, apoptosis, G2 chromosomal radiosensitivity and G0 micronucleus assay were used to compare case and control lymphocyte radiation responses., Results: Five hundred and thirty genes were up-regulated and 819 down-regulated by ionising radiation. Irradiated samples were identified with an overall cross-validated error rate of 3.4%. Prediction analyses to classify cases and controls using unirradiated (0Gy), irradiated (4Gy) or radiation response (4-0Gy) expression profiles correctly identified samples with, respectively, 25%, 22% or 18.5% error rates. Significant inter-sample variation was observed for all cellular endpoints but cases and controls could not be distinguished., Conclusions: Variation in lymphocyte radiosensitivity does not necessarily correlate with normal tissue response to radiotherapy. Gene expression analysis can predict of radiation exposure and may in the future help prediction of normal tissue radiosensitivity., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
32. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.
- Author
-
Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutiérrez-Enríquez S, Fuentes-Raspall MJ, Alonso-Muñoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, and Bentzen SM
- Subjects
- Alleles, Breast Neoplasms pathology, Breast Neoplasms radiotherapy, Fibrosis etiology, Genotype, Humans, Linear Models, Odds Ratio, Radiation Tolerance genetics, Radiotherapy, Adjuvant adverse effects, Risk, Breast Neoplasms genetics, Polymorphism, Single Nucleotide, Radiation Injuries genetics, Transforming Growth Factor beta1 genetics
- Abstract
Background and Purpose: Reported associations between risk of radiation-induced normal tissue injury and single nucleotide polymorphisms (SNPs) in TGFB1, encoding the pro-fibrotic cytokine transforming growth factor-beta 1 (TGF-β1), remain controversial. To overcome publication bias, the international Radiogenomics Consortium collected and analysed individual patient level data from both published and unpublished studies., Materials and Methods: TGFB1 SNP rs1800469 c.-1347T>C (previously known as C-509T) genotype, treatment-related data, and clinically-assessed fibrosis (measured at least 2years after therapy) were available in 2782 participants from 11 cohorts. All received adjuvant breast radiotherapy. Associations between late fibrosis or overall toxicity, reported by STAT (Standardised Total Average Toxicity) score, and rs1800469 genotype were assessed., Results: No statistically significant associations between either fibrosis or overall toxicity and rs1800469 genotype were observed with univariate or multivariate regression analysis. The multivariate odds ratio (OR), obtained from meta-analysis, for an increase in late fibrosis grade with each additional rare allele of rs1800469 was 0.98 (95% Confidence Interval (CI) 0.85-1.11). This CI is sufficiently narrow to rule out any clinically relevant effect on toxicity risk in carriers vs. non-carriers with a high probability., Conclusion: This meta-analysis has not confirmed previous reports of association between fibrosis or overall toxicity and rs1800469 genotype in breast cancer patients. It has demonstrated successful collaboration within the Radiogenomics Consortium., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
33. The relationship between homologous recombination repair and the sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy.
- Author
-
Somaiah N, Yarnold J, Daley F, Pearson A, Gothard L, Rothkamm K, and Helleday T
- Subjects
- Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Cycle Checkpoints radiation effects, Cyclin-Dependent Kinase Inhibitor p21 metabolism, DNA Breaks, Double-Stranded radiation effects, DNA Damage radiation effects, Epidermis metabolism, Epidermis radiation effects, Female, Humans, Middle Aged, Breast metabolism, Breast radiation effects, Breast Neoplasms radiotherapy, Radiation Tolerance, Recombinational DNA Repair genetics, Recombinational DNA Repair radiation effects
- Abstract
Purpose: A molecular understanding of tissue sensitivity to radiotherapy fraction size is missing. Here, we test the hypothesis that sensitivity to fraction size is influenced by the DNA repair system activated in response to DNA double-strand breaks (DSB). Human epidermis was used as a model in which proliferation and DNA repair were correlated over 5 weeks of radiotherapy., Experimental Design: Radiotherapy (25 fractions of 2 Gy) was prescribed to the breast in 30 women with early breast cancer. Breast skin biopsies were collected 2 hours after the 1st and 25th fractions. Samples of contralateral breast skin served as controls. Sections were coimmunostained for Ki67, cyclin A, p21, RAD51, 53BP1, and β1-integrin., Results: After 5 weeks of radiotherapy, the mean basal Ki67 density increased from 5.72 to 15.46 cells per millimeter of basement membrane (P = 0.002), of which the majority were in S/G2 phase, as judged by cyclin A staining (P < 0.0003). The p21 index rose from 2.8% to 87.4% (P < 0.0001) after 25 fractions, indicating cell cycle arrest. By week 5, there was a 4-fold increase (P = 0.0003) in the proportion of Ki67-positive cells showing RAD51 foci, suggesting increasing activation of homologous recombination., Conclusions: Cell cycle arrest in S/G2 phase in the basal epidermis after a 5-week course of radiotherapy is associated with greater use of homologous recombination for repairing DSB. The high fidelity of homologous recombination, which is independent of DNA damage levels, may explain the low-fractionation sensitivity of tissues with high-proliferative indices, including self-renewing normal tissues and many cancers.
- Published
- 2012
- Full Text
- View/download PDF
34. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer.
- Author
-
Donovan EM, James H, Bonora M, Yarnold JR, and Evans PM
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Cone-Beam Computed Tomography, Female, Humans, Incidence, Middle Aged, Neoplasms, Radiation-Induced diagnostic imaging, Neoplasms, Second Primary diagnostic imaging, Organ Specificity, Phantoms, Imaging, Radiotherapy Dosage, Risk Assessment, Time Factors, Breast Neoplasms radiotherapy, Models, Biological, Neoplasms, Radiation-Induced epidemiology, Neoplasms, Second Primary epidemiology
- Abstract
Purpose: To compare organ specific cancer incidence risks for standard and complex external beam radiotherapy (including cone beam CT verification) following breast conservation surgery for early breast cancer., Method: Doses from breast radiotherapy and kilovoltage cone beam CT (CBCT) exposures were obtained from thermoluminescent dosimeter measurements in an anthropomorphic phantom in which the positions of radiosensitive organs were delineated. Five treatment deliveries were investigated: (i) conventional tangential field whole breast radiotherapy (WBRT), (ii) noncoplanar conformal delivery applicable to accelerated partial beast irradiation (APBI), (iii) two-volume simultaneous integrated boost (SIB) treatment, (iv) forward planned three-volume SIB, and (v) inverse-planned three volume SIB. Conformal and intensity modulated radiotherapy methods were used to plan the complex treatments. Techniques spanned the range from simple methods appropriate for patient cohorts with a low cancer recurrence risk to complex plans relevant to cohorts with high recurrence risk. Delineated organs at risk included brain, salivary glands, thyroid, contralateral breast, left and right lung, esophagus, stomach, liver, colon, and bladder. Biological Effects of Ionizing Radiation (BEIR) VII cancer incidence models were applied to the measured mean organ doses to determine lifetime attributable risk (LAR) for ages at exposure from 35 to 80 yr according to radiotherapy techniques, and included dose from the CBCT imaging., Results: All LAR decreased with age at exposure and were lowest for brain, thyroid, liver, and bladder (<0.1%). There was little dependence of LAR on radiotherapy technique for these organs and for colon and stomach. LAR values for the lungs for the three SIB techniques were two to three times those from WBRT and APBI. Uncertainties in the LAR models outweigh any differences in lung LAR between the SIB methods. Constraints in the planning of the SIB methods ensured that contralateral breast doses and LAR were comparable to WBRT, despite their added complexity. The smaller irradiated volume of the ABPI plan contributed to a halving of LAR for contralateral breast compared with the other plan types. Daily image guided radiotherapy (IGRT) for a left breast protocol using kilovoltage CBCT contributed <10% to LAR for the majority of organs, and did not exceed 22% of total organ dose., Conclusions: Phantom measurements and calculations of LAR from the BEIR VII models predict that complex breast radiotherapy techniques do not increase the theoretical risk of second cancer incidence for organs distant from the treated breast, or the contralateral breast where appropriate plan constraints are applied. Complex SIB treatments are predicted to increase the risk of second cancer incidence in the lungs compared to standard whole breast radiotherapy; this is outweighed by the threefold reduction in 5 yr local recurrence risk for patients of high risk of recurrence, and young age, from the use of radiotherapy. APBI may have a favorable impact on risk of second cancer in the contralateral breast and lung for older patients at low risk of recurrence. Intensive use of IGRT increased the estimated values of LAR but these are dominated by the effect of the dose from the radiotherapy, and any increase in LAR from IGRT is much lower than the models' uncertainties.
- Published
- 2012
- Full Text
- View/download PDF
35. Does participation in clinical trials influence the implementation of new techniques? A look at changing techniques in breast radiotherapy in the UK.
- Author
-
Venables K, Tsang Y, Ciurlionis L, Coles CE, and Yarnold JR
- Subjects
- Breast Neoplasms drug therapy, Clinical Trials as Topic standards, Female, Humans, Quality of Life, Radiotherapy methods, Radiotherapy standards, Randomized Controlled Trials as Topic methods, Randomized Controlled Trials as Topic standards, Surveys and Questionnaires, United Kingdom, Breast Neoplasms radiotherapy, Clinical Trials as Topic methods
- Abstract
Aims: To examine the effect of UK breast radiotherapy trials on the adoption of new radiotherapy techniques over the last 15 years., Materials and Methods: The data were taken from questionnaires returned to the national radiotherapy quality assurance team for each of the major trials (START, Supremo, FAST, IMPORT) with additional information sought from heads of radiotherapy physics departments where needed., Results: The peak years for the introduction of three-dimensional radiotherapy corresponded to the opening of new trials requiring these techniques. Some non-trial centres had still not implemented three-dimensional techniques for breast cancer patients at the time the most recent questionnaire was completed (2009)., Conclusion: Clinical trials provide the framework and impetus for introducing more accurate radiotherapy for UK women with early breast cancer., (Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
36. Quality assurance analysis of participating centres' protocol compliance to a UK multicentre hypofractionated breast (FAST) trial.
- Author
-
Tsang Y, Venables K, and Yarnold J
- Subjects
- Adult, Aged, Aged, 80 and over, Dose Fractionation, Radiation, Female, Humans, Middle Aged, Prevalence, Radiotherapy Dosage, Treatment Outcome, United Kingdom epidemiology, Breast Neoplasms epidemiology, Breast Neoplasms radiotherapy, Guideline Adherence statistics & numerical data, Practice Guidelines as Topic, Quality Assurance, Health Care methods, Radiotherapy Planning, Computer-Assisted standards, Radiotherapy Planning, Computer-Assisted statistics & numerical data
- Abstract
Objectives: The FAST (FASTer radiotherapy for breast radiotherapy) trial is a UK Phase 2 multicentre randomised clinical trial evaluating a five-fraction schedule of whole-breast radiotherapy following local excision of early breast cancer. The purpose of this quality assurance study was to analyse the radiotherapy planning data in order to confirm compliance with the trial protocol., Methods: 915 patients were recruited between 2004 and 2007 from 18 centres. The protocol required that all centres should use three-dimensional dose compensations to optimise radiotherapy plans. Planning techniques, maximum dose (D(max)) and dose-volume histograms from treatment plans were evaluated and compared between centres. The homogeneity of plans was tested by creating a cut-off value of 5% for the percentage of breast volume receiving >105% of the prescribed dose., Results: 672 data sets from 15 centres were available. 93% (624/672) of plans were treated using forward-planned multileaf collimator (MLC) segments, 6% with breast compensators and 1% with inverse-planned MLC segments. 94% (635/672) of patients had a D(max)≤107% of the prescribed dose. 11% (74/672) of plans delivered >105% of the prescribed dose to >5% of the breast volume., Conclusion: Reviewing the data in this study, 95% of plans submitted by centres complied with the protocol. With the improved breast radiotherapy standards shown in FAST centres, the following recommendations were suggested for future UK breast radiotherapy trials: (i) the minimum, mean and maximum dose to the whole-breast planning target volume (PTV) should be recorded and assessed; (ii) apart from having a D(max)≤107% of the prescribed dose, ≤5% of PTV should a receive dose >105% of the prescription dose.
- Published
- 2012
- Full Text
- View/download PDF
37. A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy.
- Author
-
Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, Davidson S, Dunning AM, Mills J, Murray RJ, Popanda O, Seibold P, West CM, Yarnold JR, and Symonds RP
- Subjects
- Breast Neoplasms blood supply, Cohort Studies, Female, Genetic Association Studies, Humans, Risk, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Polymorphism, Single Nucleotide, Radiation Injuries genetics, Radiotherapy adverse effects, Tumor Necrosis Factor-alpha genetics
- Abstract
Background: Response to radiotherapy varies between individuals both in terms of efficacy and adverse reactions. Finding genetic determinants of radiation response would allow the tailoring of the treatment, either by altering the radiation dose or by surgery. Despite a growing number of studies in radiogenomics, there are no well-replicated genetic association results., Methods: We carried out a candidate gene association study and replicated the result using three additional large cohorts, a total of 2036 women scored for adverse reactions to radiotherapy for breast cancer., Results: Genetic variation near the tumour necrosis factor alpha gene is shown to affect several clinical endpoints including breast induration, telangiectasia and overall toxicity. In the combined analysis homozygosity for the rare allele increases overall toxicity (P=0.001) and chance of being in the upper quartile of risk with odds ratio of 2.46 (95% confidence interval 1.52-3.98)., Conclusion: We have identified that alleles of the class III major histocompatibility complex region associate with overall radiotherapy toxicity in breast cancer patients by using internal replication through a staged design. This is the first well-replicated report of a genetic predictor for radiotherapy reactions.
- Published
- 2012
- Full Text
- View/download PDF
38. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy.
- Author
-
Tsang Y, Haviland J, Venables K, and Yarnold J
- Subjects
- Aged, Aged, 80 and over, Breast Neoplasms surgery, Disease-Free Survival, Dose-Response Relationship, Radiation, Female, Follow-Up Studies, Humans, Logistic Models, Mastectomy, Segmental methods, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Staging, Prospective Studies, Radiotherapy Dosage, Radiotherapy, Adjuvant, Risk Assessment, Survival Analysis, Treatment Outcome, United Kingdom, Breast Neoplasms mortality, Breast Neoplasms radiotherapy, Dose Fractionation, Radiation, Neoplasm Recurrence, Local pathology
- Abstract
Background and Purpose: Linear quadratic models predict that hypofractionation increases the biological effect of physical dose inhomogeneity. The clinical significance of this effect was tested retrospectively in a trial of adjuvant breast hypofractionation., Methods: The UK FAST trial randomised 915 women after breast conservation surgery between standard fractionation and two dose levels of a 5-fraction regimen delivering 5.7 or 6.0 Gy fractions in 5 weeks, using 3D dosimetry. Logistic regression tested for association between the absolute volumes receiving different isodose level >100% of prescribed dose (hotspots) and the risk of change in 2-year photographic breast appearance. The strength of this association was compared between control and hypofractionated groups., Results: Three hundred and ninety datasets from 11 participating centres were available for analysis. At 2 years post-randomisation, 81 (20.8%) had mild change and 24 (6.2%) had marked change in photographic breast appearance. After adjusting for breast size and surgical deficit, there was no statistically significant association between the risk of 2-year change in breast appearance and dose inhomogeneity in either the control or hypofractionated schedules, according to the various definitions of hotspots analysed. The magnitude of the effect of dosimetry on 2-year change in breast appearance did not vary significantly between control and hypofractionated schedules for any of the dosimetry parameters (p>0.05 for all heterogeneity tests)., Conclusion: Dose inhomogeneity had no greater impact on the risk of 2-year change in photographic breast appearance after hypofractionated breast radiotherapy than after standard fractionation., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
39. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
- Author
-
Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, and Sculpher MJ
- Subjects
- Adult, Aged, Antineoplastic Agents economics, Antineoplastic Combined Chemotherapy Protocols economics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms economics, Chemotherapy, Adjuvant economics, Cost-Benefit Analysis, Cyclophosphamide economics, Cyclophosphamide therapeutic use, Docetaxel, Epirubicin economics, Epirubicin therapeutic use, Female, Fluorouracil economics, Fluorouracil therapeutic use, Health Care Costs, Humans, Methotrexate economics, Methotrexate therapeutic use, Middle Aged, Prognosis, Quality-Adjusted Life Years, Taxoids economics, Taxoids therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy
- Abstract
Background: The risk of recurrence following surgery in women with early breast cancer varies, depending upon prognostic factors. Adjuvant chemotherapy reduces this risk; however, increasingly effective regimens are associated with higher costs and toxicity profiles, making it likely that different regimens may be cost-effective for women with differing prognoses. To investigate this we performed a cost-effectiveness analysis of four treatment strategies: (1) no chemotherapy, (2) chemotherapy using cyclophosphamide, methotrexate, and fluorouracil (CMF) (a first generation regimen), (3) chemotherapy using Epirubicin-CMF (E-CMF) or fluorouracil, epirubicin, and cyclophosphamide (FEC60) (a second generation regimens), and (4) chemotherapy with FEC60 followed by docetaxel (FEC-D) (a third generation regimen). These adjuvant chemotherapy regimens were used in three large UK-led randomised controlled trials (RCTs)., Methods: A Markov model was used to simulate the natural progression of early breast cancer and the impact of chemotherapy on modifying this process. The probability of a first recurrent event within the model was estimated for women with different prognostic risk profiles using a parametric regression-based survival model incorporating established prognostic factors. Other probabilities, treatment effects, costs and quality of life weights were estimated primarily using data from the three UK-led RCTs, a meta-analysis of all relevant RCTs, and other published literature. The model predicted the lifetime costs, quality adjusted life years (QALYs) and cost-effectiveness of the four strategies for women with differing prognoses. Sensitivity analyses investigated the impact of uncertain parameters and model assumptions., Findings: For women with an average to high risk of recurrence (based upon prognostic factors and any other adjuvant therapies received), FEC-D appeared most cost-effective assuming a threshold of £20,000 per QALY for the National Health Service (NHS). For younger low risk women, E-CMF/FEC60 tended to be the optimal strategy and, for some older low risk women, the model suggested a policy of no chemotherapy was cost-effective. For no patient group was CMF chemotherapy the preferred option. Sensitivity analyses demonstrated cost-effectiveness results to be particularly sensitive to the treatment effect estimate for FEC-D and the future price of docetaxel., Interpretation: To our knowledge, this analysis is the first cost-effectiveness comparison of no chemotherapy, and first, second, and third generation adjuvant chemotherapy regimens for early breast cancer patients with differing prognoses. The results demonstrate the potential for different treatment strategies to be cost-effective for different types of patients. These findings may prove useful for policy makers attempting to formulate cost-effective treatment guidelines in the field of early breast cancer., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
40. Multicentric breast cancer: clonality and prognostic studies.
- Author
-
Eeles R, Knee G, Jhavar S, Mangion J, Ebbs S, Gui G, Thomas S, Coppen M, A'hern R, Gray S, Cooper C, Bartek J, and Yarnold J
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Case-Control Studies, Disease-Free Survival, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Mutation, Polymerase Chain Reaction, Polymorphism, Single-Stranded Conformational, Prognosis, Tumor Suppressor Protein p53 metabolism, Breast Neoplasms genetics, Breast Neoplasms pathology, Tumor Suppressor Protein p53 genetics
- Abstract
Clonality of multicentric breast cancer has traditionally been difficult to assess. We aimed to assess this using analysis of TP53 status (expression and mutation status). These results were then incorporated into an analysis of prognostic factors in multicentric tumours in a 10-year follow up study. Clonal status of multicentric breast cancer foci (n = 88 foci) was determined by immunohistochemical and molecular studies of TP53 in a total of 40 patients. Prognostic factors from these patients were also compared with 80 age- and stage-matched controls with unicentric breast cancer from the Royal Marsden NHS Foundation Trust Breast Cancer Database. Our results indicate that multicentric breast cancer foci were polyclonal within an individual patient in at least 10 patients (25%) with respect to immunohistochemical staining and in four patients (10%) with respect to abnormal band shifts on single strand conformational polymorphism (SSCP) molecular analysis. No individual variable was predictive of multicentric or unicentric disease. However, there was a worse overall survival in the multicentric breast cancer patients in whom at least two cancer foci stained positively on TP53 immunohistochemistry compared with the matched control group (P = 0.04). In conclusion, these results suggest that a proportion of multicentric breast cancer foci are polyclonal with respect to TP53 status and that TP53 over-expression predicts for a poorer prognosis in multicentric breast cancer.
- Published
- 2011
- Full Text
- View/download PDF
41. Evaluation of implanted gold seeds for breast radiotherapy planning and on treatment verification: a feasibility study on behalf of the IMPORT trialists.
- Author
-
Coles CE, Harris EJ, Donovan EM, Bliss P, Evans PM, Fairfoul J, Mackenzie C, Rawlings C, Syndikus I, Twyman N, Vasconcelos J, Vowler SL, Wilkinson JS, Wilks R, Wishart GC, and Yarnold J
- Subjects
- Breast Neoplasms diagnostic imaging, Feasibility Studies, Female, Humans, Mastectomy, Segmental, Breast Neoplasms radiotherapy, Gold, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy, Image-Guided methods, Radiotherapy, Intensity-Modulated methods, Tomography, X-Ray Computed methods
- Abstract
Background and Purpose: We describe a feasibility study testing the use of gold seeds for the identification of post-operative tumour bed after breast conservation surgery (BCS)., Materials and Methods: Fifty-three patients undergoing BCS for invasive cancer were recruited. Successful use was defined as all six seeds correctly positioned around the tumour bed during BCS, unique identification of all implanted seeds on CT planning scan and ≥ 3 seeds uniquely identified at verification to give couch displacement co-ordinates in 10/15 fractions. Planning target volume (PTV) margin size for four correction strategies were calculated from these data. Variability in tumour bed contouring was investigated with five radiation oncologists outlining five CT datasets., Results: Success in inserting gold seeds, identifying them at CT planning and using them for on-treatment verification was recorded in 45/51 (88%), 37/38 (97%) and 42/43 (98%) of patients, respectively. The clinicians unfamiliar with CT breast planning consistently contoured larger volumes than those already trained. Margin size ranged from 10.1 to 1.4mm depending on correction strategy., Conclusion: It is feasible to implant tumour bed gold seeds during BCS. Whilst taking longer to insert than surgical clips, they have the advantage of visibility for outlining and verification regardless of the ionising radiation beam quality. Appropriate correction strategies enable margins of the order of 5mm as required by the IMPORT trials however, tackling clinician variability in contouring is important., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
42. Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?
- Author
-
Goldsmith C, Haviland J, Tsang Y, Sydenham M, and Yarnold J
- Subjects
- Aged, Aged, 80 and over, Breast Neoplasms pathology, Female, Humans, Middle Aged, Photography, Radiotherapy Dosage, Risk Factors, Breast pathology, Breast Neoplasms radiotherapy, Radiotherapy Planning, Computer-Assisted
- Abstract
Background and Purpose: Large breast size is associated with an increased risk of late adverse effects after breast conservation surgery and radiotherapy, even when 3D dosimetry is used. The purpose of this study is to test the hypothesis that residual dose inhomogeneity is sufficient to explain the association., Methods: Patients previously treated after breast conservation surgery with whole breast radiotherapy using 3D dosimetry and followed up in the UK FAST hypofractionation trial were selected for this analysis. The residual level of dose inhomogeneity across the whole breast treatment volume was used to test for association between residual dosimetry and post-treatment change in breast appearance at 2 years post-radiotherapy., Results: At 2 years, 201/279 (72%) of women had no change in photographic breast appearance, 61 (22%) had mild change and 17 (6%) had marked change. Breast size and dosimetry were both significantly associated with late effects in univariate analyses, but only breast size remained an independent significant risk factor for change in breast appearance when included in a multiple regression model together with other prognostic factors (p=0.006 for trend)., Conclusion: Large-breasted women are more likely to suffer change in breast size and shape after whole breast radiotherapy delivered using 3D dosimetry, but residual dose inhomogeneity is insufficient to explain the association., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
43. Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy.
- Author
-
Chua ML, Somaiah N, A'Hern R, Davies S, Gothard L, Yarnold J, and Rothkamm K
- Subjects
- Aged, Case-Control Studies, Female, Humans, Lymphocytes metabolism, Microscopy, Fluorescence, Randomized Controlled Trials as Topic, Retrospective Studies, Statistics, Nonparametric, Breast Neoplasms radiotherapy, Chromosome Aberrations, DNA Breaks, Double-Stranded, Lymphocytes radiation effects, Radiation Tolerance genetics
- Abstract
Purpose: To test the association of DNA double-strand break (DSB) repair and chromosomal radiosensitivity in ex vivo irradiated blood lymphocytes with late-onset normal tissue responses following breast radiotherapy., Methods: Breast cancer patients with minimal (controls) or marked late radiotherapy changes (cases) were retrospectively selected. DSB were quantified by γH2AX/53BP1 immunofluorescence microscopy 0.5 and 24 h after exposure of unstimulated blood lymphocytes to 0.5 and 4 Gy X-rays, respectively. Chromosomal aberrations were scored in blood lymphocyte metaphases after 6 Gy X-rays., Results: Despite similar foci levels at 0.5 h in cases (n=7) and controls (n=7), foci levels 24 h after 4 Gy irradiation differed significantly between them (foci per cell were 12.8 in cases versus 10.2 in controls, p=0.004). Increased chromosomal radiosensitivity was also observed in cases (aberrations per cell were 5.84 in cases versus 3.79 in controls, p=0.001) with exchange and deletion type aberrations contributing equally to the difference between cases and controls. Residual foci correlated with formation of deletions (Spearman's R=0.589, p=0.027) but not exchanges (R=0.367, p=0.197) in blood lymphocytes from the same patients., Conclusions: Higher levels of exchange type aberrations observed among radiosensitive breast cancer patients suggest a role for DSB misrepair, in addition to residual damage, as determinants of late normal tissue damage. Correlation of residual foci levels with deletion type aberration yields in the same cohort confirms their mechanistic linkage., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
44. Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin.
- Author
-
Chua ML, Somaiah N, Bourne S, Daley F, A'hern R, Nuta O, Davies S, Herskind C, Pearson A, Warrington J, Helyer S, Owen R, Yarnold J, and Rothkamm K
- Subjects
- Aged, Analysis of Variance, Biopsy, Dose-Response Relationship, Radiation, Female, Humans, Immunoenzyme Techniques, Breast Neoplasms radiotherapy, DNA Breaks, Double-Stranded radiation effects, Endothelial Cells radiation effects, Fibroblasts radiation effects, Keratinocytes radiation effects, Radiation Injuries genetics, Skin cytology, Skin radiation effects
- Abstract
Purpose: The aim of this study was to compare inter-individual and inter-cell type variation in DNA double-strand break (DSB) repair following in vivo irradiation of human skin., Materials and Methods: Duplicate 4mm core biopsies of irradiated and unirradiated skin were collected from 35 patients 24h after 4Gy exposure using 6MeV electrons. Residual DSB were quantified by scoring 53BP1 foci in dermal fibroblasts, endothelial cells, superficial keratinocytes and basal epidermal cells., Results: Coefficients of inter-individual variation for levels of residual foci 24h after in vivo irradiation of skin were 39.9% in dermal fibroblasts, 44.3% in endothelial cells, 32.9% in superficial keratinocytes and 46.4% in basal epidermal cells (p<0.001, ANOVA). In contrast, the coefficient of inter-cell type variation for residual foci levels was only 11.3% in human skin between the different epidermal and dermal cells (p=0.034, ANOVA). Foci levels between the different skin cell types were correlated (Pearson's R=0.855-0.955, p<0.001)., Conclusions: Patient-specific factors appear to be more important than cell type-specific factors in determining residual foci levels following in vivo irradiation of human skin., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
45. Planning with intensity-modulated radiotherapy and tomotherapy to modulate dose across breast to reflect recurrence risk (IMPORT High trial).
- Author
-
Donovan EM, Ciurlionis L, Fairfoul J, James H, Mayles H, Manktelow S, Raj S, Tsang Y, Tywman N, Yarnold J, and Coles C
- Subjects
- Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Electrons therapeutic use, Female, Fiducial Markers, Heart radiation effects, Humans, Lung radiation effects, Photons therapeutic use, Radiotherapy Dosage, Thermoluminescent Dosimetry methods, Tomography, X-Ray Computed, Tumor Burden, Breast Neoplasms prevention & control, Breast Neoplasms radiotherapy, Neoplasm Recurrence, Local prevention & control, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy, Intensity-Modulated methods
- Abstract
Purpose: To establish planning solutions for a concomitant three-level radiation dose distribution to the breast using linear accelerator- or tomotherapy-based intensity-modulated radiotherapy (IMRT), for the U.K. Intensity Modulated and Partial Organ (IMPORT) High trial., Methods and Materials: Computed tomography data sets for 9 patients undergoing breast conservation surgery with implanted tumor bed gold markers were used to prepare three-level dose distributions encompassing the whole breast (36 Gy), partial breast (40 Gy), and tumor bed boost (48 or 53 Gy) treated concomitantly in 15 fractions within 3 weeks. Forward and inverse planned IMRT and tomotherapy were investigated as solutions. A standard electron field was compared with a photon field arrangement encompassing the tumor bed boost volume. The out-of-field doses were measured for all methods., Results: Dose-volume constraints of volume >90% receiving 32.4 Gy and volume >95% receiving 50.4 Gy for the whole breast and tumor bed were achieved. The constraint of volume >90% receiving 36 Gy for the partial breast was fulfilled in the inverse IMRT and tomotherapy plans and in 7 of 9 cases of a forward planned IMRT distribution. An electron boost to the tumor bed was inadequate in 8 of 9 cases. The IMRT methods delivered a greater whole body dose than the standard breast tangents. A contralateral lung volume >2.5 Gy was increased in the inverse IMRT and tomotherapy plans, although it did not exceed the constraint., Conclusion: We have demonstrated a set of widely applicable solutions that fulfilled the stringent clinical trial requirements for the delivery of a concomitant three-level dose distribution to the breast., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
46. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities.
- Author
-
Yarnold J, Bentzen SM, Coles C, and Haviland J
- Subjects
- Breast Neoplasms pathology, Breast Neoplasms surgery, Dose Fractionation, Radiation, Early Diagnosis, Female, Heart radiation effects, Humans, Linear Models, Lung radiation effects, Mastectomy, Organs at Risk radiation effects, Radiation Tolerance, Radiotherapy, Adjuvant adverse effects, Radiotherapy, Adjuvant methods, Randomized Controlled Trials as Topic, Relative Biological Effectiveness, Risk, Tumor Burden, Breast Neoplasms radiotherapy
- Published
- 2011
- Full Text
- View/download PDF
47. Hypofractionated adjuvant whole breast radiotherapy: progress and prospects.
- Author
-
Yarnold J and Haviland J
- Subjects
- Adult, Aged, Breast Neoplasms surgery, Female, Humans, Middle Aged, Radiotherapy, Adjuvant methods, Treatment Outcome, United Kingdom, Breast Neoplasms radiotherapy, Dose Fractionation, Radiation, Mastectomy, Segmental
- Abstract
Published results of randomised trials involving >7000 women confirm the safety and efficacy of hypofractionated schedules of adjuvant radiotherapy for women with early breast cancer using fraction sizes between 2 and 3 Gy assuming appropriate downward adjustments to total dose. Unnecessary concerns relating to heart tolerance, suboptimal dose distribution and duration of follow up need not discourage the routine adoption of 15- or 16-fraction schedules in women treated by breast conservation surgery for early breast cancer. Regardless of fractionation regimen, dose escalation to the index quadrant in high risk subgroups will result in a greater relative increase in late adverse effects than tumour control, a therapeutic disadvantage that can only be overcome by exploiting a marked dose-volume effect. A 15-fraction schedule of whole breast radiotherapy is unlikely to represent the lower limits of hypofractionation, and the preliminary results of a 5-fraction regimen are encouraging.
- Published
- 2010
- Full Text
- View/download PDF
48. Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy.
- Author
-
Martin S, Sydenham M, Haviland J, A'Hern R, Owen R, Bliss J, and Yarnold J
- Subjects
- Alleles, Case-Control Studies, Codon, Dose Fractionation, Radiation, Female, Follow-Up Studies, Genetic Variation, Genotype, Humans, Phenotype, Photography, Radiotherapy Dosage, Retrospective Studies, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Polymorphism, Single Nucleotide, Radiation Tolerance genetics, Radiotherapy adverse effects
- Abstract
Purpose: To test for association between single nucleotide polymorphisms at the TGFβ1 locus and the risk of late normal tissue injury following whole breast radiotherapy., Methods: A retrospective study compared the number of variant alleles at -509 and codons 10 and 25 of the TGFβ1 locus in women followed up in two prospective clinical trials who developed either marked radiotherapy adverse effects or no adverse effects after matching on fractionation schedule, breast size, surgical deficit, chemotherapy and length of follow up., Results: Median follow up in the two trials was 7.4 (maximum 15) years and 5.3 (maximum 5.3) years. 1237/1716 (72%) women with photographic assessments of radiotherapy adverse effects were alive and well, and 147/1237 (12%) potential cases with the most marked change in photographic change in breast appearance were matched to potential controls recording no change. In an unmatched analysis of 82 cases and 108 controls, no significant difference in the number of genetic variants was observed., Conclusions: No association was detected between sequence variations at the TGFβ1 locus and the risk of late adverse effects of breast radiotherapy., (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
49. Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer.
- Author
-
Gothard L, Haviland J, Bryson P, Laden G, Glover M, Harrison S, Woods M, Cook G, Peckitt C, Pearson A, Somaiah N, Stanton A, Mortimer P, and Yarnold J
- Subjects
- Chronic Disease, Endpoint Determination, Female, Humans, Lymph Nodes radiation effects, Lymphedema diagnostic imaging, Middle Aged, Quality of Life, Radionuclide Imaging, Risk Factors, Statistics, Nonparametric, Surveys and Questionnaires, Treatment Outcome, Arm diagnostic imaging, Breast Neoplasms radiotherapy, Hyperbaric Oxygenation, Lymphedema etiology, Lymphedema therapy
- Abstract
Background: A non-randomised phase II study suggested a therapeutic effect of hyperbaric oxygen (HBO) therapy on arm lymphoedema following adjuvant radiotherapy for early breast cancer, justifying further investigation in a randomised trial., Methods: Fifty-eight patients with ≥ 15% increase in arm volume after supraclavicular ± axillary radiotherapy (axillary surgery in 52/58 patients) were randomised in a 2:1 ratio to HBO (n=38) or to best standard care (n=20). The HBO group breathed 100% oxygen at 2.4 atmospheres absolute for 100 min on 30 occasions over 6 weeks. Primary endpoint was ipsilateral limb volume expressed as a percentage of contralateral limb volume. Secondary endpoints included fractional removal rate of radioisotopic tracer from the arm, extracellular water content, patient self-assessments and UK SF-36 Health Survey Questionnaire., Findings: Of 53/58 (91.4%) patients with baseline assessments, 46 had 12-month assessments (86.8%). Median volume of ipsilateral limb (relative to contralateral) at baseline was 133.5% (IQR 126.0-152.3%) in the control group, and 135.5% (IQR 126.5-146.0%) in the treatment group. Twelve months after baseline the median (IQR) volume of the ipsilateral limb was 131.2% (IQR 122.7-151.5%) in the control group and 133.5% (IQR 122.3-144.9%) in the treatment group. Results for the secondary endpoints were similar between randomised groups., Interpretation: No evidence has been found of a beneficial effect of HBO in the treatment of arm lymphoedema following primary surgery and adjuvant radiotherapy for early breast cancer., (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
50. Pushing the limits of hypofractionation for adjuvant whole breast radiotherapy.
- Author
-
Yarnold J and Haviland J
- Subjects
- Breast Neoplasms pathology, Dose-Response Relationship, Radiation, Female, Humans, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Adjuvant, Breast Neoplasms radiotherapy, Dose Fractionation, Radiation
- Abstract
Randomised trials report no disadvantages for hypofractionation based on 2.67 Gy fractions of adjuvant whole breast radiotherapy in terms of local tumour control and late adverse effects. Current 15- or 16-fraction schedules may not represent the limits of this approach, and limited data suggest that fewer larger fractions can be delivered safely provided appropriate downward adjustments are made to the total dose. Therapeutic gain will be undermined if breast cancer proves to be, on average, significantly less sensitive to fraction size than the dose-limiting late reacting normal tissues. If so, shortening overall treatment time might wholly or partially offset these limitations, and these uncertainties are addressed in ongoing or planned trials. Meanwhile, the experience of accelerated partial breast irradiation suggests a strong volume effect for late normal tissue damage. Schedules that may be safe when delivered to small partial volumes cannot be assumed to be safe if delivered to larger partial volumes or to the whole breast. Based on current evidence, testing the effectiveness of a 5-fraction schedule of hypofractionated whole breast radiotherapy appears to be a realisable research objective., (Copyright (c) 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.